000			04633nam a2200433 c4500
999			_c7311 _d7311
001			7311
003			ES-MaUEC
005			20201203160831.0
006			a||||fo|||| 00| 0
007			cr nn nnnanaaa
008			190716s2019 gw a o |||| 0|eng d
020			_a9783030165505
024	7		_a10.1007/978-3-030-16550-5 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-VaUE
050		4	_aRC280 _b.T35 2019 EB
245	0	0	_aTargeted Therapies in Lung Cancer : Management Strategies for Nurses and Practitioners _cedited by Marianne Davies, Beth Eaby-Sandy.
250			_a1st ed. 2019.
264		1	_aCham _bSpringer International Publishing : _bImprint: Springer _c2019.
300			_a1 recurso en línea (V, 120 páginas) _b9 ilustraciones, 8 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aMedicine (Springer-11650)
505	0		_aChapter 1. Introduction -- Chapter 2. Introduction to Mutation Testing -- Chapter 3. Nursing Considerations with EGFR inhibitors in NSCLC -- Chapter 4. Nursing Considerations with ALK and ROS1 inhibitors in NSCLC -- Chapter 5. BRAF in Non-Small Cell Lung Cancer -- Chapter 6. Mechanisms of acquired resistance to targeted therapy in NSCLC: Role of Repeat Biopsy and Nursing Considerations -- Chapter 7. The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer -- Chapter 8. The Role of Anti-Angiogenic Agents (VEGF) -- Chapter 9. Nursing Considerations for Patients Treated with Targeted Therapies.
520	3		_aThis book aims to educate nurses and advanced practice providers (APP's) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP's are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP's with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.
988			_aSegundosemestre_2019_Medicine
650		7	_2embne _9168954 _aPulmones _xCáncer
700	1		_aDavies, Marianne _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aEaby-Sandy, Beth _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
710	2		_aSpringerLink (Online service) _9106937
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783030165499
776	0	8	_iPrinted edition: _z9783030165512
776	0	8	_iPrinted edition: _z9783030165529
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-16550-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
998			_db _feng _ggw _h0 _zSI